• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Antidepressants May Boost Cancer Antitumor Immunity

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models. Read More

Braftovi and Erbitux Plus Chemo Improves Outcomes for BRAF V600E+ mCRC

by MM360 Staff | May 30, 2025 | Uncategorized

Source: CureToday articles Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting. Read More

Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer. Read More

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial’s primary end point for those with myelofibrosis. Read More

Guiding Light: A Journey of Support and Hope

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles Christine Simonelli, B.S.N., RN, CCRC, OCN, is amazing, and goes out of her way to help patients and providers. Read More

Tracing a Five-Generation Cancer Legacy Through Genetic Discovery

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease myself. Read More
« Older Entries
Next Entries »

Recent Content

  • Oral safusidenib begins trial as maintenance for high-grade glioma
  • Outcomes of relapse after teclistamab therapy in multiple myeloma
  • Canada agency backs coverage of new ovarian cancer drug
  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT